SCHEMBL13063867

SCHEMBL13063867

CC(C)(C)n1nc(Cc2cccc3c(F)cccc23)c2c(N)ncnc21

nearest known ligand 0.77

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SRC P12931 14/20 0.77
ABL1 P00519 6/20 0.77
PRKD3 O94806 4/20 0.77
PRKD1 Q15139 4/20 0.77
PRKD2 Q9BZL6 4/20 0.77
RIPK2 O43353 2/20 0.77
FYN P06241 2/20 0.77
CDK2 P24941 2/20 0.77
CSK P41240 2/20 0.77
MAPK8 P45983 2/20 0.77
CAMK2A Q9UQM7 2/20 0.77
PRKACA P17612 1/20 0.77
CSNK1A1 P48729 1/20 0.77
CSNK1E P49674 1/20 0.77
MAPK14 Q16539 1/20 0.77
CDK12 Q9NYV4 1/20 0.77
AKT1 P31749 1/20 0.58
HCK P08631 1/20 0.53
CSNK1D P48730 1/20 0.50
PRKCE Q02156 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13019738 0.94 SRC (0.73) SRCABL1PRKD3PRKD1PRKD2
SCHEMBL12551827 0.89 SRC (0.69) SRCABL1PRKD3PRKD1PRKD2
SCHEMBL12551804 0.89 SRC (0.72) SRCABL1PRKD3PRKD1PRKD2
SCHEMBL13019848 0.88 SRC (0.68) SRCABL1PRKD3PRKD1PRKD2
SCHEMBL1964002 0.87 SRC (1.00) SRCABL1PRKD3PRKD1PRKD2
SCHEMBL29390287 0.87 SRC (1.00) SRCABL1PRKD3PRKD1PRKD2
SCHEMBL29387799 0.87 SRC (1.00) SRCABL1PRKD3PRKD1PRKD2
SCHEMBL12551826 0.85 SRC (0.64) SRCABL1PRKD3PRKD1PRKD2
SCHEMBL13019708 0.83 SRC (0.74) SRCABL1PRKD3PRKD1PRKD2
SCHEMBL13063869 0.83 SRC (0.77) SRCABL1PRKD3PRKD1PRKD2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100331297-A1 MODULATION OF PROTEIN TRAFFICKING FOLDRX PHARMACEUTICALS, INC. (US) 2010-12-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100331297-A1 MODULATION OF PROTEIN TRAFFICKING RAB1A, COPB1, GOLT1B SRC 1332/4885ABL1 1725/4885PRKD3 1366/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.